Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons that can correct multiple disease-causing mutations at once. Unlike ...

Here’s how extinct DNA could help us in the present—and the future. Yeah, we know—it’s not a dire wolf. In early 2025, the Texas biotech company Colossal Biosciences landed with a splash on the cover ...

I hate to break this to you, but every child is a genetic experiment – and nature doesn’t care if things go wrong. Our genomes are awful messes created by conflicting evolutionary forces, and every ...

Add Yahoo as a preferred source to see more of our stories on Google. Dec. 22—dbeard @dominionpost.com MORGANTOWN — Customers of Preston County Public Service District No. 1 will be seeing public ...

This year marked a pivotal moment in the quest to treat Huntington’s disease, a rare but devastating form of dementia. Scientists found that an experimental gene therapy slowed the condition’s ...

KJ Muldoon received a groundbreaking new treatment earlier this year. The baby saved from a rare disease by a first-ever personalized gene fix has reached a big milestone, taking his first steps ahead ...

Dec. 16—dbeard @dominionpost.com MORGANTOWN — The Preston County Public Service District No. 1 briefly discussed Tuesday evening the rate increase proposal sitting before the state Public Service ...

There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University’s College of Medicine and the UMass Chan Medical School have achieved ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Revolutions in gene therapy are rapidly changing the landscape of modern medicine. Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike ...

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene-writing program, inking a deal that lets it in on a prospect for alpha-1 antitrypsin deficiency (AATD) through a $150 million ...

Instead of requiring personalized gene edits for each patient, the new approach could create a standardized method to use for many diseases. By Pam Belluck and Carl Zimmer Gene-editing therapies offer ...